Investing.com -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) stock surged 19% following the company’s announcement of strong early sales for PALSONIFY and positive clinical trial results for its CAH treatment candidate.
The San Diego-based endocrine disease specialist reported unaudited and preliminary net product revenue exceeding $5 million for PALSONIFY in the fourth quarter of 2025, its first full quarter on the market. The acromegaly treatment, which received FDA approval in September 2025, has garnered over 200 enrollment forms and attracted more than 125 unique prescribers by the end of December.
Simultaneously, Crinetics released positive results from the fourth cohort of its Phase 2 trial for atumelnant, an oral ACTH receptor antagonist being developed for congenital adrenal hyperplasia (CAH). The trial showed that atumelnant (80 mg) achieved a 67% mean reduction in androstenedione levels while allowing 88% of participants who completed 12 weeks of treatment to successfully reduce their glucocorticoid dose to physiologic replacement levels.
"I’m very proud of our team’s strong execution of Palsonify’s launch in acromegaly," said Scott Struthers, founder and CEO of Crinetics. "We are delivering impressive results, highlighted by over 200 enrollment forms in the first three months after FDA approval, a broad prescriber base, and continued momentum toward favorable payer coverage."
The company reported that approximately half of newly filled PALSONIFY prescriptions were reimbursed without requiring bridge supplies, and most prior authorizations have 12-month durations, suggesting favorable payer reception.
Atumelnant’s safety profile remained favorable in the trial, with no serious adverse events, no treatment-related severe adverse events, and notably, no hepatic transaminase adverse events reported among participants.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
